COX / inflammatory signalling

Scientific explanation

-2–PGE2 signalling can promote , immune suppression and epithelial proliferation, notably in colorectal neoplasia.

Cancers where relevant

Colorectal cancer MSI-high colorectal cancer MSS colorectal cancer

Compounds that intersect this pathway

Celecoxib

Selective -2 reducing PGE2. Relevant to -associated epithelial neoplasia; cardiovascular risk and lack of broad anticancer approval constrain interpretation.

Evidence in mapped cancers: Clinical / Human Evidence · In Vivo · In Vitro

Omega-3 fatty acids

EPA/DHA alter eicosanoid balance and membrane signalling. Cachexia and hypotheses exist; they are not cytotoxic oncology drugs.

Evidence in mapped cancers: Clinical / Human Evidence · Mechanistically Plausible

Convergence partners

Other pathways that co-occur with COX / inflammatory signalling on mapped adjunct records: Angiogenesis, Immune suppression.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.